Esophageal stent for perforated esophagus
top of page
Internal Medicine
Public·91 members
Wegdan Abdalla
Aug 14
•
Medical Devices Visible:
1. Endotracheal Tube (ETT)
2. Central Venous Catheter
3. Chest Tubes
4. ECG Leads
Metabolic Dysfunction–Associated Steatohepatitis (MASH) and Emerging Treatments
Overview:
Metabolic dysfunction–associated steatohepatitis (MASH), a prevalent liver disease worldwide, is primarily driven by obesity and currently lacks effective treatments. Glucagon-like peptide-1 (GLP-1) receptor agonists, emerging as promising anti-obesity treatments, may offer a potential therapeutic option for MASH. Recent studies explore the efficacy of these agents, particularly when combined with other incretin hormones or complementary pathway molecules.
Semaglutide Study:
A phase 2 trial investigated , a GLP-1 receptor agonist, in MASH patients. While semaglutide achieved steatohepatitis resolution in 40-59% of participants, it did not significantly reduce liver fibrosis, a crucial surrogate endpoint. Furthermore, it failed to improve histological outcomes in patients with cirrhosis.
Enhanced GLP-1 Receptor Agonist-Based Treatments:
bottom of page
I think consolidation in Lt lower lobe and Rt lower posterior lobe and bilateral pleural effusion
There is homogenous opacity in Rt lower lobe